This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Carl Uli Bialucha, Ph.D.
VP Drug Discovery at Immunitas Therapeutics


Carl Uli Bialucha, Ph.D. received his BSc in Molecular Genetics from the University of Sussex in the UK and completed his PhD in Cell Biology at the Medical Research Council Laboratory for Molecular Cell Biology at University College London, UK. Uli moved to the US in 2007 to join Prof. Scott Lowe’s lab at Cold Spring Harbor Laboratory, where he completed his postdoctoral research and established novel genetic mouse models of cancer to study tumor suppressor gene networks. Before joining Immunitas, Uli spent nine years within the Oncology Drug Discovery group at the Novartis Institutes for Biomedical Research in several leadership roles of increasing responsibility. In his last role at Novartis, Uli led the Oncology Biotherapeutics group, overseeing progression of a portfolio of therapies across multiple mechanisms of action, including T-cell engaging bispecific antibodies, antibody drug conjugates and targeted radioligand therapies – with several programs having entered clinical development.

Agenda Sessions

  • Immune Oncology Antibodies

  • Therapeutic Targeting of a Novel NK- and T-cell Immune Checkpoint

    On Demand